Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - erlotinibhydrochlorid - filmovertrukne tabletter - 150 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - erlotinibhydrochlorid - filmovertrukne tabletter - 25 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - betamethason, calcipotriol - salve - 50 mikrog/g+0,5 mg/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

leo pharma a/s - betamethasondipropionat, calcipotriol hydrate - salve - 50+500 mikrogram/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - betamethasondipropionat, calcipotriol hydrate - salve - 50+500 mikrogram/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - betamethason, calcipotriol - salve - 50 mikrog/g+0,5 mg/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - betamethasondipropionat, calcipotriol hydrate - gel - 50 mikrog/g+0,5 mg/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abacus medicine a/s - betamethasondipropionat, calcipotriol hydrate - gel - 50 mikrog/g+0,5 mg/g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

epione medicine aps - betamethasondipropionat, calcipotriol hydrate - gel - 50 mikrog/g+0,5 mg/g